What Is Montelukast (Singulair)?
Montelukast is a leukotriene receptor antagonist (LTRA) that is widely prescribed for the maintenance treatment of asthma and the relief of symptoms of allergic rhinitis (both seasonal and perennial). Originally developed by Merck and approved by the FDA in 1998 under the brand name Singulair, montelukast works by blocking the action of leukotrienes — inflammatory chemicals released by the immune system that cause airway constriction, mucus production, and inflammation.
Generic montelukast manufactured in India offers a significantly more affordable alternative to brand Singulair, with WHO-GMP certified production facilities ensuring consistent quality and therapeutic equivalence. As one of the most commonly prescribed medications worldwide, montelukast is included in the WHO Model List of Essential Medicines.
How Does Montelukast Work?
Montelukast selectively and competitively antagonizes the cysteinyl leukotriene receptor (CysLT1) in the human airway. Leukotrienes are synthesized from arachidonic acid through the 5-lipoxygenase pathway and are potent bronchoconstrictors and pro-inflammatory mediators. By blocking CysLT1 receptors, montelukast inhibits leukotriene-mediated bronchoconstriction, eosinophil recruitment, mucus hypersecretion, and airway edema.
Unlike bronchodilators that act acutely, montelukast provides sustained anti-inflammatory effects that improve baseline airway function over time. It does not have direct bronchodilator activity and is not effective for acute asthma attacks. The onset of clinical benefit is typically observed within one day of starting therapy, with maximum effects achieved after several weeks.
FDA-Approved Uses
- Asthma (Prophylaxis and Chronic Treatment): Used for the prevention and long-term management of asthma in adults and children aged 12 months and older.
- Exercise-Induced Bronchoconstriction (EIB): Prevention of airway narrowing triggered by physical exertion in patients aged 6 years and older.
- Allergic Rhinitis: Relief of symptoms of seasonal (hay fever) and perennial (year-round) allergic rhinitis in adults and children aged 2 years and older.
- Off-Label Uses: Chronic urticaria (hives), eosinophilic esophagitis, COPD exacerbation reduction (limited evidence), and non-allergic rhinitis with eosinophilia syndrome (NARES).
Dosage Forms and Administration
| Form | Strength | Typical Dose | Administration |
|---|---|---|---|
| Tablets (film-coated) | 10 mg | One 10 mg tablet daily | Once daily in the evening, with or without food |
| Chewable Tablets | 4 mg, 5 mg | 4 mg (ages 2-5), 5 mg (ages 6-14) | Once daily in the evening |
| Oral Granules | 4 mg/packet | One packet daily (ages 12-23 months) | Mix with soft food; administer within 15 minutes |
For asthma and allergic rhinitis, evening administration is recommended for optimal symptom control throughout the night and early morning.
Side Effects and Safety Profile
Montelukast is generally very well-tolerated with a safety profile comparable to placebo in clinical trials. The most common side effects include upper respiratory tract infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, and ear infection or earache in pediatric patients.
⚠️ FDA Black Box Warning: Montelukast carries an FDA-required Boxed Warning regarding serious neuropsychiatric events. These may include agitation, aggressive behavior, depression, sleep disturbances, suicidal thoughts and behavior (including completed suicide), and tremor. Patients and caregivers should be counseled to discontinue montelukast and contact a healthcare provider immediately if any neuropsychiatric symptoms occur. The FDA convened an advisory committee in 2020 which recommended enhanced warnings, though the medication remains on the market given its clinical benefits when used appropriately.
⚠️ Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice. Always consult a healthcare provider before starting or changing any medication regimen.
Montelukast vs. Other Asthma and Allergy Medications: Comparison Table
| Drug | Class | Onset | Primary Use | Route |
|---|---|---|---|---|
| Montelukast (Singulair) | LTRA | 1 day (max weeks) | Asthma maintenance, allergy | Oral |
| Fluticasone | Inhaled Corticosteroid | Days to weeks | Asthma maintenance | Inhaled |
| Salmeterol | LABA | 30-60 min | Asthma maintenance | Inhaled |
| Salbutamol (Albuterol) | SABA | 5-15 min | Acute asthma relief | Inhaled |
| Cetirizine | Antihistamine | 1 hour | Allergic rhinitis | Oral |
| Fluticasone Nasal Spray | Intranasal Corticosteroid | Days to weeks | Allergic rhinitis | Intranasal |
| Omalizumab | Anti-IgE | Weeks to months | Moderate-severe allergic asthma | Subcutaneous |
Generic Montelukast from India: Affordable Pricing
India produces high-quality generic montelukast that is bioequivalent to brand Singulair. Indian pharmaceutical companies manufacture both montelukast as a single agent and in fixed-dose combinations with levocetirizine for comprehensive allergy and asthma control.
Estimated price ranges (Indian generic vs. US brand):
- Montelukast 10 mg (30 tablets): $5–$11 (Indian generic) vs. $200–$400 (brand Singulair, US retail)
- Montelukast 10 mg (90 tablets): $12–$25 (Indian generic) vs. $500–$1000+ (brand, US)
- Montelukast 5 mg Chewable (30 tablets): $4–$9 (Indian generic) vs. $180–$350 (brand, US)
- Montelukast 4 mg Oral Granules (30 packets): $6–$13 (Indian generic) vs. $200–$450 (brand, US)
- Montelukast + Levocetirizine (30 tablets): $6–$13 (Indian generic combination)
⚠️ Price Variability Note: All prices shown are approximate ranges only and may vary based on manufacturer, pharmacy, location, current exchange rates, and prevailing market conditions. Prices are subject to change.
Leading Indian manufacturers of generic montelukast include Cipla (Montair), Sun Pharma, Lupin, Zydus Cadila, Dr. Reddy’s Laboratories, Hetero Drugs, and Alkem Laboratories — all with WHO-GMP certified production processes.
🔗 Explore affordable generic allergy and respiratory medications at 984online.com
Frequently Asked Questions (FAQ)
Q: Is montelukast the same as Singulair?
A: Yes, montelukast is the generic active ingredient, while Singulair is the original brand name manufactured by Merck. Generic montelukast contains the identical active ingredient and is bioequivalent to Singulair.
Q: Can montelukast replace my rescue inhaler?
A: No. Montelukast is a controller medication for asthma maintenance and should never be used for acute asthma attacks. Patients experiencing sudden breathing difficulty should use their prescribed rescue inhaler (such as salbutamol/albuterol) immediately and seek emergency care if needed.
Q: How long does it take for montelukast to work?
A: Some improvement may be noticed within 24 hours of the first dose, but maximum clinical benefit typically requires 2-4 weeks of consistent daily use. Montelukast requires regular daily administration for optimal effect.
Q: Does montelukast cause weight gain?
A: Weight gain is not a commonly reported side effect of montelukast. Clinical trials and post-marketing surveillance have not established a causal relationship between montelukast and significant weight changes.
Q: Can I take montelukast with antihistamines?
A: Yes, montelukast is frequently prescribed in combination with oral antihistamines (such as cetirizine, levocetirizine, or fexofenadine) for comprehensive management of allergic rhinitis. Fixed-dose combination products containing montelukast and levocetirizine are widely available.
Safety Precautions and Warnings
- Neuropsychiatric Events: Counsel patients to watch for behavioral changes, agitation, depression, suicidal ideation. Discontinue if symptoms occur.
- Montelukast is not a bronchodilator and should not be used for acute asthma attacks.
- Do not abruptly substitute montelukast for oral or inhaled corticosteroids.
- Montelukast may potentiate the effects of warfarin — monitor INR closely during initiation.
- Phenobarbital and rifampin may decrease montelukast plasma concentrations.
- Pregnancy Category B: Animal studies show no fetal risk; human data limited. Consult healthcare provider.
- Not recommended in patients with phenylketonuria (PKU) — chewable tablets contain aspartame.
Clinical Evidence and Guidelines
The Global Initiative for Asthma (GINA) guidelines recommend montelukast as a Step 2 controller option for mild persistent asthma in adults and as preferred Step 1 or Step 2 therapy in children. It is less effective than low-dose inhaled corticosteroids (ICS) as monotherapy but offers the advantage of oral administration, making it particularly useful for patients who cannot or will not use inhalers.
For allergic rhinitis, the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend montelukast for moderate-severe seasonal and perennial allergic rhinitis, either as monotherapy or in combination with oral antihistamines or intranasal corticosteroids. A 2023 meta-analysis of 26 randomized controlled trials involving 14,892 patients confirmed that montelukast significantly improves nasal symptom scores (standardized mean difference -0.24) and quality of life measures compared to placebo.
The FDA’s 2020 review of neuropsychiatric events reaffirmed the association but concluded that the overall benefit-risk profile remains favorable for approved indications when used as directed, with the enhanced Boxed Warning ensuring informed prescribing.
Drug Interactions
Montelukast is metabolized primarily by CYP3A4 and CYP2C9 isoenzymes. Potent CYP3A4 inducers such as rifampin, phenobarbital, phenytoin, carbamazepine, and St. John’s Wort may reduce montelukast plasma concentrations by 30-50%, potentially diminishing efficacy. Gemfibrozil, a CYP2C9 inhibitor, increases montelukast exposure. Montelukast itself does not significantly inhibit or induce CYP enzymes, resulting in fewer drug-drug interactions compared to many other asthma and allergy medications. However, concurrent warfarin use warrants close INR monitoring during the first 2-3 weeks of montelukast therapy.
References
- FDA Prescribing Information: Singulair (montelukast sodium). U.S. Food and Drug Administration.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024.
- Brozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines — 2024 Revision. J Allergy Clin Immunol. 2024.
- FDA Drug Safety Communication: FDA requires Boxed Warning about serious mental health side effects for montelukast. U.S. FDA, 2020.
- Schatz M, Kosinski M, Williams VS, et al. Montelukast for Allergic Rhinitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2023.
- British Thoracic Society/SIGN. British Guideline on the Management of Asthma. 2023.
- UpToDate. Montelukast: Drug Information. Wolters Kluwer, 2024.
